Pathophysiologically relevant concentrations of tumor necrosis factor- α promote progressive left ventricular dysfunction and remodeling in rats

Circulation

Volumn 97, Issue 14, 1998, Pages 1382-1391

  Bozkurt, Biykem ^a   Kribbs, Scott B ^b   Clubb Jr , Fred J ^c   Michael, Lloyd H ^a   Didenko, Vladimir V ^a   Hornsby, Peter J ^a   Seta, Yukihiro ^a   Oral, Hakan ^a   Spinale, Francis G ^b   Mann, Douglas L ^a,d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c TEXAS HEART INSTITUTE   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Contractility; Cytokines; Heart failure; Remodeling

Indexed keywords

FC RECEPTOR; HYBRID PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CONTINUOUS INFUSION; CONTROLLED STUDY; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE REMODELING; HEMODYNAMIC PARAMETERS; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 0032515950     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.14.1382     Document Type: Article

References (55)

1. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;223:236-241.
2. McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumour necrosis factor in 'cachectic' patients with severe chronic heart failure. Br Heart J. 1991;66:356-358.
3. Wiedermann CJ, Beimpold H, Herold M, Knapp E, Braunsteiner H. Increased levels of serum neopterin and decreased production of neutrophil Superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol. 1993;22:1897-1901.
4. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704-711.
5. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O. Tumor necrosis factor soluble receptors in patients with various degrees of congestive failure. Circulation. 1995;92:1479-1486.
6. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-1206.
7. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321:280-287.
8. Hegewisch S, Weh HJ, Hossfeld DK. TNF-induced cardiomyopathy. Lancet. 1990;2:294-295.
9. Millar AB, Singer M, Meager A, Foley NM, Johnson NM, Rook GA. Tumor necrosis factor in bronchopulmonary secretions of patients with adult respiratory distress syndrome. Lancet. 1989;2:712-713.
10. Mann DL, Young JB. Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest. 1994;105:897-904.
11. Seta Y, Shan K, Buzkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Cardiac Failure. 1996;2:243-249.
12. Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation. 1995;92:1379-1382.
13. Natanson C, Eichenholz PW, Danner RL, Eichacker W, Hoffman D, Kuo SM, Banks TJ, MacViottie TJ, Parrillo JE. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med. 1989;169:823-832.
14. Eichenholz PW, Eichacker PQ, Hoffman WD, Banks SM, Parrillo JE, Danner RL, Natanson C. Tumor necrosis factor challenges in canines: patterns of cardiovascular dysfunction. Am J Physiol. 1992;263:H668-H675.
15. Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, Visner MS. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-α in conscious dogs. J Clin Invest. 1992;90:389-398.
16. Walley KR, Hebert PC, Wakai Y, Wilcox PG, Road JD, Cooper DJ. Decrease in left ventricular contractility after tumor necrosis factor-α infusion in dogs. J Appl Physiol. 1994;76:1060-1067.
17. Murray DR, Freeman GL. Tumor necrosis factor-α induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res. 1996;78:154-160.
18. Gaskill HV. Continuous infusion of tumor necrosis factor: mechanisms of toxicity in the rat. J Surg Res. 1988;44:664-671.
19. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology. 1992;130:43-52.
20. Michie HR, Sherman ML, Spriggs DR, Rounds J, Christie M, Wilmore DW, Chronic TNF infusion causes anorexia but not accelerated nitrogen loss. Ann Surg. 1989;209:19-24.
21. Socher SH, Friedman A, Martinez D. Recombinant human tumor necrosis factor induces reductions in food intake and body weight in mice. J Exp Med. 1988;167:1957-1962.
22. Kapadia S, Lee JR, Torre-Amione G, Birdsall HH, Ma TS, Mann DL. Tumor necrosis factor gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest. 1995;96:1042-1052.
23. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux RB, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, Silverman NH, Tajik AJ. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358-367.
24. Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effect on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790-804.
25. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invent. 1993;92:2303-2312.
26. Oral H, Mann DL. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-α in the adult mammalian cardiac myocyte. J Biol Chem. 1997;272:4836-4842.
27. Coroneos E, Martinez M, McKenna S, Kester M. Differential regulation of sphingomyelinase and ceramidase activities by growth factors and cytokines. J Biol Chem. 1995;270:23305-23309.
28. Gardin JM, Siri FM, Kitsis RN, Edwards JG, Leinwand LA. Echocardiographic assessment of left ventricular mass and systolic function in mice. Circ Res. 1995;76:907-914.
29. Spinale FG, Zellner JL, Tomita M, Crawford FA, Zile MR. Relationship between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia-induced cardiomyopathy. Circ Res. 1991;69:1058-1067.
30. Spinale FG, Ishihra K, Zile MR, Defryte G, Crawford FA, Carabello BA. The structural basis for changes in left ventricular function and geometry because of chronic mitral regurgitation and after correction of volume overload. J Thorac Cardiovasc Surg. 1993;106:1147-1157.
31. Whittaker P, Kloner RA, Boughner DR, Pickering JG. Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol. 1994;89:397-410.
32. Spinale FG, Tomita M, Zellner JL, Cook JC, Crawford FA, Zile MR. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol. 1991;261:H308-H318.
33. Itoh G, Tamura J, Suzuki M, Suzuki Y, Ikeda H, Koike M, Nomura M, Jie T, Ito K. DNA fragmentation of human infarcted myocardial cells demonstrated by the nick end labeling method and DNA agarose gel electrophoresis. Am J Pathol. 1995;146:1325-1331.
34. Didenko VV, Hornsby PJ. Presence of double-strand breaks with single base 3′ overhangs in cells undergoing apoptosis but not necrosis. J Cell Biol. 1996;135:1369-1375.
35. Bishop SP, Oparil S, Reynolds RH, Drummond JL. Regional myocyte size in normotensive and spontaneously hypertensive rats. Hypertension. 1979;1:378-383.
36. Mendez J, Keys A. Density and composition of mammalian muscle. Metabolism. 1960;9:184-188.
37. Loud AV, Anversa P. Biology of disease: morphometric analysis of biologic processes. Lab Invest. 1984;50:250-261.
38. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151:1548-1561.
39. Tsujimoto M, Yokota S, Vilcek J, Weissmann G. Tumor necrosis factor provokes Superoxide anion generation from neutrophils. Biochem Biophys Res Commun. 1986;137:1094-1100.
40. Gulick TS, Chung MK, Pieper SJ, Lange LG, Schreiner GF. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness. Proc Natl Acad Sci U S A. 1989;86:6753-6757.
41. Balligand JL, Ungureanu D, Kelly RA, Kobzik L, Pimental D, Michel T, Smith TW. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest. 1993;91:2314-2319.
42. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:387-389.
43. Kapadia S, Torre-Amione G, Yokoyama T, Mann DL. Soluble tumor necrosis factor binding proteins modulate the negative inotropic effects of TNF-α in vitro. Am J Physiol. 1995;37:H517-H525.
44. Westermarck J, Hakkinen L, Fiers W, Kahari VM. TNF-R55-specific form of human tumor necrosis factor-α induces collagenase gene expression by human skin fibroblasts. J Invest Dermatol. 1995;105:197-202.
45. Dollery CM, McEvvan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995;77:863-868.
46. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254.
47. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, Heublein DM, Kao PC, Edwards WD, Burnett JC. Endothelin in human congestive heart failure. Circulation. 1994;89:1580-1586.
48. Lerman A, Hildebrand FL Jr, Aarhus LL, Burnett JC Jr. Endothelin has biological actions at pathophysiological concentrations. Circulation. 1991;83:1808-1814.
49. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996;384:353-355.
50. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;346:732-736.
51. Schwartz K, Carrier L, Mercadier JJ, Lompre AM, Boehler KR. Molecular phenotype of the hypertrophied and failing myocardium. Circulation. 1993;(suppl VII):VII-5-VIl-10.
52. Weber KT, Pick R, Janicki JS, Lakier JB. Inadequate collagen tethers in dilated cardiopathy. Am Heart J. 1988;116:1641-1646.
53. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, Glembotski CC, Quintana PJE, Sabbadini RA. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98:2854-2865.
54. Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol. 1988;141:2629-2634.
55. Klefstrom J, Vastrik I, Saksela E, Valle J, Eilers M, Alitalo K. c-Myc induces cellular susceptibility to the cytotoxic action of TNF-α. EMBO J. 1994;13:5442-5450.